Drug/Small Molecule:
carbamazepine

Available Guidelines

  1. CPIC Dosing Guideline for carbamazepine and HLA-B
  2. Professional Society Guideline for carbamazepine and HLA-A
  3. Professional Society Guideline for carbamazepine and HLA-B


last updated 08/19/2014

Professional Society Guideline for carbamazepine and HLA-A

Summary

The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-A*31:01 genotype when prescribing carbamazepine (CBZ). They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-A*31:01 allele.

There's more of this guideline. Read more.


last updated 03/11/2014

Professional Society Guideline for carbamazepine and HLA-B

Summary

The Canadian Pharmacogenomics Network for Drug Safety (CPNDS) clinical recommendation group has published guidelines for the use of HLA-B*15:02 genotype when prescribing carbamazepine (CBZ). They recommend that carbamazepine not be prescribed for CBZ-naive patients who carry at least one HLA-B*15:02 allele.

There's more of this guideline. Read more.


PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for carbamazepine and HLA-B

This label is on the FDA Biomarker List
Genetic testing required

Summary

The FDA-approved label for carbamazepine (Tegretol) states that screening of patients with ancestry in genetically at-risk populations (patients of Asian descent) for the presence of the HLA-B*1502 allele should be carried out prior to initiating treatment with Tegretol due to a high risk of serious and sometimes fatal dematologic reactions. Patients positive for the HLA-B*1502 allele should not be treated with Tegretol, unless the benefit clearly outweighs the risk. Association with the HLA-A*3101 and the risk of developing hypersensitivity reactions to carbamazepine is also mentioned in the label, though testing for this allele is not required.

Annotation

Excerpts from the carbamazepine (Tegretol) drug label:

Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity. Across Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in <1% of the population in Japan and Korea. HLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans).


Prior to initiating Tegretol therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLAB*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry. Tegretol should not be used in patients positive for HLAB*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN. Over 90% of Tegretol treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at risk patients currently on Tegretol.


Retrospective case-control studies in patients of European, Korean, and Japanese ancestry have found a moderate association between the risk of developing hypersensitivity reactions and the presence of HLA-A*3101, an inherited allelic variant of the HLA-A gene, in patients using carbamazepine. These hypersensitivity reactions include SJS/TEN, maculopapular eruptions, and Drug Reaction with Eosinophilia and Systemic Symptoms...The risks and benefits of Tegretol therapy should be weighed before considering Tegretol in patients known to be positive for HLA-A*3101.


Application of HLA genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502 positive and HLA-A*3101 positive patients treated with Tegretol will not develop SJS/TEN or other hypersensitivity reactions, and these reactions can still occur infrequently in HLA-B*1502 negative and HLA-A*3101 negative patients of any ethnicity. The role of other possible factors in the development of, and morbidity from, SJS/TEN and other hypersensitivity reactions, such as antiepileptic drug (AED) dose, compliance, concomitant medications, comorbidities, and the level of dermatologic monitoring, have not been studied.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the carbamazepine drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Depression
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Epidermal Necrolysis, Toxic
    • Warnings section
    • source: PHONT
  • Epilepsy
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Hypersensitivity
    • Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Leukemia
    • Warnings section, Precautions section
    • source: PHONT
  • Seizures
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • CYP3A4
    • Drug interactions section, metabolism/PK
    • source: FDA Label
  • HLA-A
    • Warnings section, toxicity
    • source: FDA Label
  • HLA-B
    • Boxed warning section, Warnings section, Laboratory tests section, Information for patients section, toxicity
    • source: FDA Label

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
HLA-B*1502 Carbamazepine Sensitivity rs3909184 , rs2844682 , HLA-B HLA-B*1502

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP3A5 *1A N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *3A N/A N/A N/A
No VIP available No VIP available VA HLA-A *02:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *24:02:01:01 N/A N/A N/A
No VIP available CA VA HLA-A *31:01:02 N/A N/A N/A
No VIP available No VIP available VA HLA-A *33:03:01 N/A N/A N/A
No VIP available No VIP available VA HLA-A *74:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *07:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *08:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *13:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *15:01:01:01 N/A N/A N/A
VIP CA VA HLA-B *15:02:01 N/A N/A N/A
No VIP available CA VA HLA-B *15:11:01 N/A N/A N/A
No VIP available CA VA HLA-B *15:18:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *27:05:02 N/A N/A N/A
No VIP available CA VA HLA-B *40:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *44:02:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *48:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *51:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-B *57:01:01 N/A N/A N/A
No VIP available CA VA HLA-B *58:01 N/A N/A N/A
No VIP available CA VA HLA-B *59:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *01:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *03:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *03:03:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *03:04:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *06:02:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *07:04:01 N/A N/A N/A
No VIP available No VIP available VA HLA-C *14:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DQB1 *03:03:02:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *03:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *07:01:01:01 N/A N/A N/A
No VIP available No VIP available VA HLA-DRB1 *14:05:01 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10068980 161287847G>A, 18651G>A, 188-4880G>A, 6099120G>A
G > A
Intronic
No VIP available CA VA
rs1043620 -1103A>G, 222T>C, 3069342C>C, 3077402C>C, 3098516C>C, 31723755T>C, 31783755T>C, 3293335C>C, 4081A>G, Ile74=
C > T
5' Flanking
Ile74Ile
No VIP available CA VA
rs1045642 208920T>A, 208920T>C, 25171488A>G, 25171488A>T, 3435T>A, 3435T>C, 87138645A>G, 87138645A>T, ABCB1*6, ABCB1: 3435C>T, ABCB1: C3435T, ABCB1: c.3435C>T, ABCB1:3435C>T, Ile1145=, Ile1145Ile, MDR1 3435C>T, MDR1 C3435T, PGP C3435T, c.3435C>T, mRNA 3853C>T
A > T
A > G
Synonymous
Ile1145Ile
No VIP available CA VA
rs1051740 19537412T>C, 226019633T>C, 26837T>C, 337T>C, EPHX1: Y113H, NM_000120.2: c.337T>C, NT_004559.13: g.2221786T>C, Tyr113His, c.337T>C, mRNA 378T>C, mRNA 612T>C, p.Tyr113His
T > C
Missense
Tyr113His
No VIP available No Clinical Annotations available VA
rs1112122 -27+13614C>A, 151606004G>T, 18827C>A, 2523942G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs1128503 1236T>C, 167964T>C, 25043506A>G, 87550285A>G, ABCB1 1236C>T, ABCB1*8, ABCB1: c.1236T>C, ABCB1:1236C>T, ABCB1:1236T>C, Gly412=, Gly412Gly, mRNA 1654T>C, p.Gly412Gly
A > G
Not Available
Gly412Gly
No VIP available No Clinical Annotations available VA
rs1157122 161319314T>C, 50118T>C, 6130587T>C, 856+1258T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs1633021 1047292T>C, 1047328T>C, 1047662T>C, 1047672T>C, 1050518C>C, 1084540T>C, 1262980C>C, 21101C>C, 29686869T>C, 29746869T>C
T > C
Not Available
No VIP available CA VA
rs17183814 16361807G>A, 166152389G>A, 56G>A, 61478G>A, Arg19Lys
G > A
Missense
Arg19Lys
No VIP available CA VA
rs1800629 -308, -308G>A, -488G>A, 2828572G>A, 2836669G>A, 2873832G>A, 2885915G>A, 2922737G>A, 3052647A>A, 31483031G>A, 31543031G>A, 4682G>A, 8156G>A, TNF alpha -308G/A, TNF2, TNF:, TNF:-308 G/A, TNF:-308G/A
G > A
5' Flanking
No VIP available CA VA
rs2032582 186947T>A, 186947T>G, 25193461A>C, 25193461A>T, 2677A, 2677G, 2677T, 2677T>A, 2677T>G, 3095G>T/A, 87160618A>C, 87160618A>T, 893 Ala, 893 Ser, 893 Thr, ABCB1*7, ABCB1: 2677G>T/A, ABCB1: 2677T/A>G, ABCB1: A893S, ABCB1: G2677T/A, ABCB1: c.2677G>T/A, ABCB1:2677G>A/T, ABCB1:2677G>T/A, ABCB1:A893T, Ala893Ser/Thr, MDR1, MDR1 G2677T/A, Ser893Ala, Ser893Thr, mRNA 3095G>T/A, p.Ala893Ser/Thr
A > T
A > C
Missense
Ser893Ala
Ser893Thr
No VIP available No Clinical Annotations available VA
rs2071197 115+308G>A, 13226527G>A, 3+308G>A, 43030435G>A, 50-4263G>A, 50995G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs211037 161528280C>T, 38633C>T, 588C>T, 6339553C>T, Asn196=
C > T
Synonymous
Asn196Asn
No VIP available CA VA
rs2227956 1478C>T, 3063859G>A, 3071920A>A, 3093033A>A, 31718272G>A, 31778272G>A, 3287853A>A, 9564C>T, Thr493Met
A > G
Missense
Thr493Met
No VIP available No Clinical Annotations available VA
rs2229944 1194C>T, 1308C>T, 160721319G>A, 5532592G>A, Ala398=, Ala436=
G > A
Synonymous
Ala436Ala
No VIP available CA VA
rs2234922 19544185A>G, 226026406A>G, 33610A>G, 416A>G, EPHX1: H139R, His139Arg, NM_000120.2: c.416A>G, NT_004559.13: g.2228559A>G, mRNA 457A>G, mRNA 691A>G, p.His139Arg
A > G
Missense
His139Arg
No VIP available CA VA
rs2273697 101563815G>A, 1249G>A, 26353G>A, 52368279G>A, ABCC2: c.1249G>A, ABCC2:1249G>A, ABCC2:V417I, ABCC2:c.1249G>A, Val417Ile, p.V417I
G > A
Missense
Val417Ile
No VIP available No Clinical Annotations available VA
rs2276707 1055-17C>G, 1055-17C>T, 119534153C>G, 119534153C>T, 26029299C>G, 26029299C>T, 39823C>G, 39823C>T, 827-17C>G, 827-17C>T, 938-17C>G, 938-17C>T
C > G
C > T
Intronic
No VIP available CA VA
rs2279020 1059+15G>A, 161322889G>A, 53693G>A, 6134162G>A
G > A
Intronic
No VIP available CA VA
rs2290732 *470A>G, 161324898A>G, 55702A>G, 6136171A>G
A > G
3' UTR
No VIP available CA VA
rs2298771
C > T
Not Available
Ala1056Thr
No VIP available CA VA
rs2304016 16377921A>G, 166168503A>G, 77592A>G, 971-32A>G, SCN2A:IVS7-32A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs2461817 -22-1425A>C, 119524651A>C, 26019797A>C, 30321A>C, 96-1425A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs2606345 -27+606G>T, 45807733C>A, 7294C>A, 75017176C>A
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs2740574 -392G>A, 37414939C>T, 4713G>A, 5'-flanking region -392A>G, 99382096C>T, CYP3A4*1B, CYP3A4-V, CYP3A4:-392A>G
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs28365062 10174938A>G, 69964271A>G, 735A>G, Thr245=
A > G
Synonymous
Thr245Thr
No VIP available No Clinical Annotations available VA
rs28365063 10173277A>G, 372A>G, 69962610A>G, Arg124=
A > G
Synonymous
Arg124Arg
No VIP available No Clinical Annotations available VA
rs2848716 2721765G>C, 2734396G>C, 2900667G>C, 31327967G>C, 31387967G>C
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs2894342 33714394C>A, 33774394C>A
C > A
Not Available
No VIP available No Clinical Annotations available VA
rs3130690 2579419T>T, 2619646T>T, 2632844G>T, 2666437G>T, 2799173G>T, 31225935G>T, 31285935G>T
T > G
Not Available
No VIP available No Clinical Annotations available VA
rs3219151 *135C>T, 161128914C>T, 5940187C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs3740066 101604207C>T, 3972C>T, 52408671C>T, 66745C>T, ABCC2:3972C>T, I1324I, Ile1324=
C > T
Synonymous
Ile1324Ile
No VIP available CA VA
rs3812718 166909544C>T, 17118962C>T, 25606G>A, 603-91G>A
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs3814055 -1135C>T, -1570C>T, 119500035C>T, 25995181C>T, 5705C>T
C > T
5' Flanking
No VIP available No Clinical Annotations available VA
rs3814058 *1232T>C, 119537291T>C, 26032437T>C, 42961T>C
T > C
3' UTR
No VIP available No Clinical Annotations available VA
rs4148386 101548468G>A, 11006G>A, 208-3523G>A, 52352932G>A, 804C>T
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs4148739 186516A>G, 2482-236A>G, 25193892T>C, 87161049T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs4148740 195462T>C, 25184946A>G, 2686-1911T>C, 87152103A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs4688040 -22-1985G>T, 119524091G>T, 26019237G>T, 29761G>T, 96-1985G>T
G > T
Intronic
No VIP available No Clinical Annotations available VA
rs4828696 -27+37622A>G, 151581996T>C, 2499934T>C, 42835A>G
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs506770 1695G>C, 2608C>G, 3070815G>C, 3078875C>C, 3099989C>C, 31725228G>C, 31785228G>C, 3294808C>C, Ala565=
C > G
Synonymous
Ala565Ala
No VIP available No Clinical Annotations available VA
rs511310 46240004A>G, 5942908A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs6883877 161278338C>T, 6089611C>T, 74+448C>T, 9142C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs6892782 161269783T>C, 587T>C, 6081056T>C
T > C
Not Available
No VIP available No Clinical Annotations available VA
rs717620 -24C>T, 101542578C>T, 5116C>T, 52347042C>T, ABCC2: 5'UTR, ABCC2:(-24)C>T, mRNA 118C>T
C > T
5' UTR
No VIP available No Clinical Annotations available VA
rs7438135 -900G>A, 10172006G>A, 69961339G>A
G > A
5' Flanking
No VIP available No Clinical Annotations available VA
rs7439366 10175005T>C, 69964338T>C, 802T>C, Tyr268His, UGT2B7*2, UGT2B7:802C>T, UGT2B7:H268Y, UGT2B7Y
T > C
Missense
Tyr268His
No VIP available CA VA
rs750332 2617-47G>A, 2892621T>T, 2900686T>T, 2937851T>T, 2949933T>T, 2986737T>T, 3116665T>T, 3139-47G>A, 31547050C>T, 31607050C>T, 3286-47G>A, 3304-47G>A
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs7643645 -22-579A>G, 119525497A>G, 26020643A>G, 31167A>G, 96-579A>G
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs7668258 -161T>C, 10172745T>C, 69962078T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs776746 12083G>A, 219-237G>A, 321-1G>A, 37303382C>T, 581-237G>A, 689-1G>A, 99270539C>T, CYP3A5*1, CYP3A5*3, CYP3A5*3C, CYP3A5:6986A>G, g.6986A>G, intron 3 splicing defect, rs776746 A>G
C > T
Acceptor
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • CBZ
  • Carbamezepine
  • carbamazepine
Trade Names
  • Apo-Carbamazepine
  • Atretol
  • Biston
  • Calepsin
  • Carbamazepen
  • Carbatrol
  • Carbazepine
  • Carbelan
  • Epitol
  • Equetro
  • Finlepsin
  • Karbamazepin
  • Lexin
  • Neurotol
  • Novo-Carbamaz
  • Nu-Carbamazepine
  • Sirtal
  • Stazepin
  • Stazepine
  • Taro-Carbamazepine
  • Taro-Carbamazepine Cr
  • Tegretal
  • Tegretol
  • Tegretol Chewtabs
  • Tegretol Cr
  • Tegretol-Xr
  • Telesmin
  • Teril
  • Timonil
Brand Mixture Names

PharmGKB Accession Id:
PA448785

Description

An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar.

Source: Drug Bank

Indication

For the treatment of epilepsy and pain associated with true trigeminal neuralgia.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Carbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.

Source: Drug Bank

Pharmacology

Carbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Avoid taking grapefruit or grapefruit juice throughout treatment.|Grapefruit can significantly increase serum levels of this product.|Take with food, increases availability and reduces irritation.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

Carbamazepine in blood is 76% bound to plasma proteins.

Source: Drug Bank

Half-Life

25-65 hours

Source: Drug Bank

Toxicity

Mild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension

Source: Drug Bank

Chemical Properties

Chemical Formula

C15H12N2O

Source: Drug Bank

Isomeric SMILES

c1ccc2c(c1)C=Cc3ccccc3N2C(=O)N

Source: OpenEye

Canonical SMILES

NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12

Source: Drug Bank

Average Molecular Weight

236.2686

Source: Drug Bank

Monoisotopic Molecular Weight

236.094963016

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Carbamazepine Pathway, Pharmacokinetics
    Stylized liver cell depicting candidate genes involved in the pharmacokinetics of carbamazepine.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
SCN5A (source: Drug Bank)

Drug Interactions

Drug Description
carbamazepine Reduces the effect of the benzodiazepine (source: Drug Bank)
carbamazepine Reduces the effect of the benzodiazepine (source: Drug Bank)
carbamazepine Carbamazepine increases or decreases the effect of theophylline (source: Drug Bank)
carbamazepine The tricyclics increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant. (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of aripiprazole (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of aripiprazole (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of the statin (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of the statin (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of bupropion (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of bupropion (source: Drug Bank)
acenocoumarol Decreases the anticoagulant effect (source: Drug Bank)
acenocoumarol Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration. (source: Drug Bank)
alprazolam Reduces the effect of the benzodiazepine (source: Drug Bank)
alprazolam Reduces the effect of the benzodiazepine (source: Drug Bank)
aminophylline Increases or decreases the effect of theophylline (source: Drug Bank)
amitriptyline The tricyclic increases the effect of carbamazepine (source: Drug Bank)
amitriptyline Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
anisindione Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration. (source: Drug Bank)
aprepitant The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant. (source: Drug Bank)
aripiprazole Decreases the effect of aripiprazole (source: Drug Bank)
aripiprazole Decreases the effect of aripiprazole (source: Drug Bank)
atorvastatin Decreases the effect of the statin (source: Drug Bank)
atorvastatin Decreases the effect of the statin (source: Drug Bank)
atracurium Decreases the effect of muscle relaxant (source: Drug Bank)
bupropion Decreases the effect of bupropion (source: Drug Bank)
bupropion Decreases the effect of bupropion (source: Drug Bank)
cimetidine Cimetidine increases the effect of carbamazepine (source: Drug Bank)
cimetidine Cimetidine increases the effect of carbamazepine (source: Drug Bank)
clarithromycin The macrolide increases the effect of carbamazepine (source: Drug Bank)
clarithromycin The macrolide, clarithromycin, may increase the effect of carbamazepine. (source: Drug Bank)
clozapine Decreases the effect of clozapine/hematologic toxicity (source: Drug Bank)
clozapine Decreases the effect of clozapine/hematologic toxicity (source: Drug Bank)
cyclosporine Decreases the effect of cyclosporine (source: Drug Bank)
cyclosporine Decreases the effect of cyclosporine (source: Drug Bank)
danazol Danazol increases the effect of carbamazepine (source: Drug Bank)
delavirdine The anticonvulsant decreases the effect of delavirdine (source: Drug Bank)
delavirdine The anticonvulsant, carbamazepine, decreases the effect of delavirdine. (source: Drug Bank)
desipramine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
desipramine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
dicumarol Decreases the anticoagulant effect (source: Drug Bank)
dicumarol Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration. (source: Drug Bank)
diltiazem Diltiazem increases the effect of carbamazepine (source: Drug Bank)
diltiazem Diltiazem increases the effect of carbamazepine (source: Drug Bank)
doxacurium Decreases the effect of muscle relaxant (source: Drug Bank)
doxepin The tricyclic increases the effect of carbamazepine (source: Drug Bank)
doxepin Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
doxycycline The anticonvulsant decreases the effect of doxycycline (source: Drug Bank)
doxycycline The anticonvulsant, carbamazepine, decreases the effect of doxycycline (source: Drug Bank)
dyphylline Increases or decreases the effect of theophylline (source: Drug Bank)
erythromycin The macrolide increases the effect of carbamazepine (source: Drug Bank)
erythromycin The macrolide, erythromycin, may increase the effect of carbamazepine. (source: Drug Bank)
ethinyl estradiol This product might cause a slight decrease of contraceptive effect (source: Drug Bank)
felbamate Decreased effect of both products (source: Drug Bank)
felbamate Decreased effect of both products (source: Drug Bank)
felodipine Decreases the effect of felodipine (source: Drug Bank)
felodipine Decreases the effect of felodipine (source: Drug Bank)
fluconazole Fluconazole increases the effect of carbamazepine (source: Drug Bank)
fluconazole Fluconazole increases the effect of carbamazepine (source: Drug Bank)
fluoxetine Fluoxetine increases the effect of carbamazepine (source: Drug Bank)
fluoxetine Fluoxetine increases the effect of carbamazepine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
gallamine triethiodide Decreases the effect of muscle relaxant (source: Drug Bank)
gefitinib This CYP3A4 inducer may reduce gefitinib plasma concentrations and pharmacological effects (source: Drug Bank)
gefitinib The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib. (source: Drug Bank)
haloperidol Decreases the effect of haloperidol (source: Drug Bank)
haloperidol Decreases the effect of haloperidol (source: Drug Bank)
imatinib Decreases levels of imatinib (source: Drug Bank)
imatinib Decreases levels of imatinib (source: Drug Bank)
imipramine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
imipramine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
indinavir Indinavir increases the effect and toxicity of carbamazepine (source: Drug Bank)
indinavir Indinavir increases the effect and toxicity of carbamazepine (source: Drug Bank)
isoniazid Carbamazepine effect is increased as is isoniazid toxicity (source: Drug Bank)
isoniazid Carbamazepine effect is increased as is isoniazid toxicity (source: Drug Bank)
isotretinoin Isotretinoine decreases the effect of carbamazepine (source: Drug Bank)
isotretinoin Isotretinoine decreases the effect of carbamazepine (source: Drug Bank)
itraconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
itraconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
josamycin The macrolide, josamycin, may increase the effect of carbamazepine. (source: Drug Bank)
ketoconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
lamotrigine Decreases the effect of lamotrigine (source: Drug Bank)
lamotrigine Decreases the effect of lamotrigine (source: Drug Bank)
levetiracetam This association may increase the risks of carbamazepine toxicity (source: Drug Bank)
levetiracetam This association may increase the risks of carbamazepine toxicity (source: Drug Bank)
levonorgestrel Decreases the contraceptive effect (source: Drug Bank)
levonorgestrel Decreases the contraceptive effect (source: Drug Bank)
lovastatin Decreases the effect of the statin (source: Drug Bank)
lovastatin Decreases the effect of the statin (source: Drug Bank)
mestranol This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
mestranol This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
methadone Decreases levels of methadone (source: Drug Bank)
methadone Decreases levels of methadone (source: Drug Bank)
methylphenidate Carbamazepine could reduce the effect of methylphenidate (source: Drug Bank)
methylphenidate Carbamazepine could reduce the effect of methylphenidate (source: Drug Bank)
metocurine Decreases the effect of muscle relaxant (source: Drug Bank)
metronidazole Metronidazole increases the effect of carbamazepine (source: Drug Bank)
metronidazole Metronidazole increases the effect of carbamazepine (source: Drug Bank)
midazolam Reduces the effect of the benzodiazepine (source: Drug Bank)
midazolam Reduces the effect of the benzodiazepine (source: Drug Bank)
mivacurium Decrease the effect of muscle relaxant (source: Drug Bank)
mivacurium Decrease the effect of muscle relaxant (source: Drug Bank)
nefazodone Nefazodone increases the effect of carbamazepine (source: Drug Bank)
nefazodone Nefazodone increases the effect of carbamazepine (source: Drug Bank)
norethindrone This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
norethindrone This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
nortriptyline The tricyclic increases the effect of carbamazepine (source: Drug Bank)
nortriptyline Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
oxtriphylline Increases or decreases the effect of theophylline (source: Drug Bank)
oxybutynin Oxybutynin may cause carbamazepine toxicity (source: Drug Bank)
pancuronium Decreases the effect of muscle relaxant (source: Drug Bank)
pancuronium Decreases the effect of muscle relaxant (source: Drug Bank)
praziquantel Markedly lower praziquantel levels (source: Drug Bank)
propoxyphene Propoxyphene increases the effect of carbamazepine (source: Drug Bank)
propoxyphene Propoxyphene increases the effect of carbamazepine (source: Drug Bank)
quinupristin This combination presents an increased risk of toxicity (source: Drug Bank)
risperidone Decreases the effect of risperidone (source: Drug Bank)
risperidone Decreases the effect of risperidone (source: Drug Bank)
ritonavir Ritonavir increases the effect of carbamazepine (source: Drug Bank)
ritonavir Ritonavir increases the effect of carbamazepine (source: Drug Bank)
sertraline Sertraline increases the effect of carbamazepine (source: Drug Bank)
sertraline Sertraline increases the effect of carbamazepine (source: Drug Bank)
simvastatin Decreases the effect of the statin (source: Drug Bank)
simvastatin Decreases the effect of the statin (source: Drug Bank)
sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
sunitinib Possible decrease in sunitinib levels (source: Drug Bank)
telithromycin Telithromycin may possibly increase this agent effect/toxicity (source: Drug Bank)
telithromycin Telithromycin may possibly increase this agent effect/toxicity (source: Drug Bank)
theophylline Increases or decreases the effect of theophylline (source: Drug Bank)
theophylline Increases or decreases the effect of theophylline (source: Drug Bank)
theophylline Increases or decreases the effect of theophylline (source: Drug Bank)
ticlopidine Ticlopidine increases the effect of carbamazepine (source: Drug Bank)
ticlopidine Ticlopidine increases the effect of carbamazepine (source: Drug Bank)
topiramate Carbamazepine may reduce levels of topiramate (source: Drug Bank)
topiramate Carbamazepine may reduce levels of topiramate (source: Drug Bank)
tramadol Reduces the efficacy of tramadol (source: Drug Bank)
tramadol Reduces the efficacy of tramadol (source: Drug Bank)
troleandomycin The macrolide increases the effect of carbamazepine (source: Drug Bank)
troleandomycin The macrolide, troleandomycin, may increase the effect of carbamazepine. (source: Drug Bank)
tubocurarine Decreases the effect of muscle relaxant (source: Drug Bank)
tubocurarine Decreases the effect of muscle relaxant (source: Drug Bank)
valproic acid Decreases the effect of valproic acid (source: Drug Bank)
vecuronium Decreases the effect of muscle relaxant (source: Drug Bank)
verapamil Verapamil increases the effect of carbamazepine (source: Drug Bank)
verapamil Verapamil increases the effect of carbamazepine (source: Drug Bank)
voriconazole Decreases the effect of voriconazole (source: Drug Bank)
voriconazole Decreases the effect of voriconazole (source: Drug Bank)
warfarin Decreases the anticoagulant effect (source: Drug Bank)
warfarin Carbamazepine may decrease the anticoagulant effect of warfarin by decreasing its serum concentration. (source: Drug Bank)
ziprasidone Increases the effect and toxicity of ziprasidone (source: Drug Bank)
ziprasidone Increases the effect and toxicity of ziprasidone (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The macrolide increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The macrolide, clarithromycin, may increase the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of clozapine, hematologic toxicity (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of clozapine, hematologic toxicity (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of cyclosporine (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of cyclosporine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The anticonvulsant decreases the effect of delavirdine (source: Drug Bank)
carbamazepine The anticonvulsant, carbamazepine, decreases the effect of delavirdine. (source: Drug Bank)
carbamazepine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the effect of divalproex by increasing it metabolism. Divalproex may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or altered (i.e. dosages adjusted). (source: Drug Bank)
carbamazepine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine The anticonvulsant decreases the effect of doxycycline (source: Drug Bank)
carbamazepine The anticonvulsant, carbamazepine, decreases the effect of doxycycline. (source: Drug Bank)
carbamazepine The macrolide increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The macrolide, erythromycin, may increase the effect of carbamazepine. (source: Drug Bank)
carbamazepine This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
carbamazepine This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
carbamazepine Decreased effect of both products (source: Drug Bank)
carbamazepine Decreased effect of both products (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of felodipine (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of felodipine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Fluvoxamine increases the effect of carbamazepine (source: Drug Bank)
carbamazepine This CYP3A4 inducer may reduce gefitinib concentrations and pharmacological effects (source: Drug Bank)
carbamazepine The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib. (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of haloperidol (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of haloperidol (source: Drug Bank)
carbamazepine Carbamazepine decreases levels of imatinib (source: Drug Bank)
carbamazepine Carbamazepine decreases levels of imatinib (source: Drug Bank)
carbamazepine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine Indinavir increases the effect and toxicity of carbamazepine (source: Drug Bank)
carbamazepine Indinavir increases the effect and toxicity of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine effect is increased as is isoniazid toxicity (source: Drug Bank)
carbamazepine Carbamazepine effect is increased as is isoniazid toxicity (source: Drug Bank)
carbamazepine Isotretinoine decreases the effect of carbamazepine (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of lamotrigine (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of lamotrigine (source: Drug Bank)
carbamazepine This association may increases the risks of carbamazepine toxicity (source: Drug Bank)
carbamazepine This association may increases the risks of carbamazepine toxicity (source: Drug Bank)
carbamazepine Carbamazepine decreases the contraceptive effect (source: Drug Bank)
carbamazepine Carbamazepine decreases the contraceptive effect (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of the statin (source: Drug Bank)
carbamazepine Carbamazepine decreases the effect of the statin (source: Drug Bank)
carbamazepine Carbamazepine decreases levels of methadone (source: Drug Bank)
carbamazepine Carbamazepine decreases levels of methadone (source: Drug Bank)
carbamazepine Carbamazepine could reduce the effect of methylphendiate (source: Drug Bank)
carbamazepine Carbamazepine could reduce the effect of methylphendiate (source: Drug Bank)
carbamazepine Metronidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Metronidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine reduces the effect of the benzodiazepine (source: Drug Bank)
carbamazepine Carbamazepine reduces the effect of the benzodiazepine (source: Drug Bank)
carbamazepine Nefazodone increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Nefazodone increases the effect of carbamazepine (source: Drug Bank)
carbamazepine This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
carbamazepine This product may cause a slight decrease of contraceptive effect (source: Drug Bank)
carbamazepine The tricyclic increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine Carbamazepine increases or decreases the effect of theophylline (source: Drug Bank)
carbamazepine Oxybutynin may cause carbamazepine toxicity (source: Drug Bank)
carbamazepine Oxybutynin may cause carbamazepine toxicity (source: Drug Bank)
carbamazepine Markedly lower praziquantel levels (source: Drug Bank)
carbamazepine Propoxyphene increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Propoxyphene increases the effect of carbamazepine (source: Drug Bank)
carbamazepine This combination presents an increased risk of toxicity (source: Drug Bank)
carbamazepine Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered. (source: Drug Bank)
carbamazepine Telithromycin may possibly increase this agent effect/toxicity (source: Drug Bank)
carbamazepine Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy. (source: Drug Bank)
carbamazepine Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided. (source: Drug Bank)
carbamazepine Carbamazepine increases or decreases the effect of theophylline (source: Drug Bank)
carbamazepine Carbamazepine increases or decreases the effect of theophylline (source: Drug Bank)
carbamazepine Ticlopidine increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Ticlopidine increases the effect of carbamazepine (source: Drug Bank)
carbamazepine Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations. (source: Drug Bank)
carbamazepine Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy. (source: Drug Bank)
carbamazepine Carbamazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. (source: Drug Bank)
carbamazepine The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
carbamazepine The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
carbamazepine Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed. (source: Drug Bank)
carbamazepine Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated. (source: Drug Bank)
carbamazepine Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to carbamazepine: 160

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity. Public health genomics. 2014. Lee Ming Ta Michael, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014. Ma Chun-Lai, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics. 2014. Bloch Katarzyna M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human UGT1A4 and UGT1A3 Conjugate 25-Hydroxyvitamin D3: Metabolite Structure, Kinetics, Inducibility and Interindividual Variability. Endocrinology. 2014. Wang Zhican, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability--a pharmacogenetic transcranial magnetic stimulation study. Epilepsia. 2014. Menzler Katja, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2014. Sun Dan, et al. PubMed
Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. Journal of dermatological science. 2014. Hsiao Yi-Hsin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study. The pharmacogenomics journal. 2014. Toh D S L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrating pharmacogenetic information and clinical decision support into the electronic health record. Journal of the American Medical Informatics Association : JAMIA. 2014. Goldspiel Barry R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenetics and genomics. 2013. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pregnane X receptor and hepatocyte nuclear factor 4alpha polymorphisms are cooperatively associated with carbamazepine autoinduction. Pharmacogenetics and genomics. 2013. Saruwatari Junji, et al. PubMed
HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. The pharmacogenomics journal. 2013. Genin E, et al. PubMed
Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Archives of disease in childhood. 2013. Chong Kok Wee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene-wide tagging study of the effects of common genetic polymorphisms in the alpha subunits of the GABAA receptor on epilepsy treatment response. Pharmacogenomics. 2013. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese. Epilepsy research. 2013. Li Li-Juan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA dermatology. 2013. Tangamornsuksan Wimonchat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenetics and genomics. 2013. Balan Shabeesh, et al. PubMed
HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. Clinical pharmacology and therapeutics. 2013. Amstutz U, et al. PubMed
HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013. Cheung Ying-Kit, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics. 2013. Haerian Batoul Sadat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing. Clinical pharmacology and therapeutics. 2013. Leckband Susan G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2013. Manuyakorn Wiparat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy. Collegium antropologicum. 2013. Sporis Davor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013. Puranik Yogita Ghodke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D(3) through CYP3A4 induction in vitro and in vivo: Implications for drug-induced osteomalacia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2012. Wang Zhican, et al. PubMed
Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China. Pharmacological reports : PR. 2013. He Xiao-Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigens (HLA) associated drug hypersensitivity: consequences of drug binding to HLA. Allergy. 2012. Yun J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA Genotype and Carbamazepine-Induced Cutaneous Adverse Drug Reactions: A Systematic Review. Clinical pharmacology and therapeutics. 2012. Yip V L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics in clinical practice and drug development. Nature biotechnology. 2012. Harper Andrew R, et al. PubMed
Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502?. Basic & clinical pharmacology & toxicology. 2012. Shi Yi-Wu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS neuroscience & therapeutics. 2012. Zhou Bo-Ting, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients. CNS neuroscience & therapeutics. 2012. Qu Jian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs. Translational research : the journal of laboratory and clinical medicine. 2012. Neuman Manuela G, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clinical and experimental pharmacology & physiology. 2012. Zhou Bo-Ting, et al. PubMed
HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain. Pain practice : the official journal of World Institute of Pain. 2012. Kulkantrakorn Kongkiat, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics. 2012. McCormack Mark, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics. 2012. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012. Hilger Eva, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annual review of pharmacology and toxicology. 2012. Bharadwaj Mandvi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*1502 allele is associated with a cross-reactivity pattern of cutaneous adverse reactions to antiepileptic drugs. The Journal of international medical research. 2012. Wang J, et al. PubMed
Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy research. 2011. Kim Sae-Hoon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011. Zhang Chunbo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asian Pacific journal of allergy and immunology / launched by the Allergy and Immunology Society of Thailand. 2011. Then Sue-Mian, et al. PubMed
Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. European journal of clinical pharmacology. 2011. Zhang Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. The Indian journal of medical research. 2011. Lakhan Ram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-Wide Association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. Orphanet journal of rare diseases. 2011. Genin Emmanuelle, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenetics and genomics. 2011. Ufer Mike, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: carbamazepine pathway. Pharmacogenetics and genomics. 2011. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clinical pharmacology and therapeutics. 2011. Price K E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia. 2011. Manna Ida, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian journal of human genetics. 2011. Kumari Ritu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia. 2011. Thompson Christopher H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human molecular genetics. 2011. Ozeki Takeshi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011. Kwan Patrick, et al. PubMed
Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure : the journal of the British Epilepsy Association. 2011. Wang Qian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. The New England journal of medicine. 2011. Chen Pei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomics and drug response. The New England journal of medicine. 2011. Wang Liewei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. The New England journal of medicine. 2011. McCormack Mark, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. European journal of neurology : the official journal of the European Federation of Neurological Societies. 2011. Depondt C, et al. PubMed
Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. International journal of dermatology. 2011. Chang Choong-Chor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-wide association study of serious blistering skin rash caused by drugs. The pharmacogenomics journal. 2011. Shen Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 2010. Kaniwa Nahoko, et al. PubMed
Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy & behavior : E&B. 2010. Wu X T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics. 2010. Potschka Heidrun. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010. Grover Sandeep, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expectations, validity, and reality in pharmacogenetics. Journal of clinical epidemiology. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of adverse drug reactions using decision tree modeling. Clinical pharmacology and therapeutics. 2010. Hammann F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. International journal of dermatology. 2010. Ding Wen Yi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al. PubMed
Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia. 2010. Tassaneeyakul Wichittra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Horstmann Sonja, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenetics and genomics. 2010. Kim Won-Joo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia. 2010. Ikeda Hiroko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Key factors in the discovery and development of new antiepileptic drugs. Nature reviews. Drug discovery. 2010. Bialer Meir, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. British journal of clinical pharmacology. 2009. Lakhan Ram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy pharmacogenetics. Pharmacogenomics. 2009. Kasperavici¿te Dalia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009. Kwan Patrick, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures. Neurology. 2009. Schlachter K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics--tailoring treatment for the outliers. The New England journal of medicine. 2009. Woodcock Janet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica; the fate of foreign compounds in biological systems. 2009. Maekawa K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009. Löscher Wolfgang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy & behavior : E&B. 2009. Lakhan R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clinical neuropharmacology. 2009. Makmor-Bakry Mohd, et al. PubMed
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008. Locharernkul Chaichon, et al. PubMed
Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian journal of dermatology, venereology and leprology. 2009. Mehta Timir Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenetics and genomics. 2008. Kwan Patrick, et al. PubMed
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics. 2008. Kaniwa Nahoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008. Ferrell P Brent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in drug transporters in ethnic populations. Clinical pharmacology and therapeutics. 2008. Cropp C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. British journal of clinical pharmacology. 2008. Abe Tomohide, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug metabolism and disposition: the biological fate of chemicals. 2008. Pearce Robin E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clinical pharmacology and therapeutics. 2008. Magnusson M O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and genomics. 2008. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neuroscience letters. 2008. Holland Katherine D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics. 2008. Gatanaga Hiroyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. The Journal of investigative dermatology. 2008. Mockenhaupt Maja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HLA-B allele associations with certain drugs are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta dermato-venereologica. 2008. Kano Yoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The association between polymorphisms in RLIP76 and drug response in epilepsy. Pharmacogenomics. 2007. Leschziner Guy D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human leukocyte antigens and drug hypersensitivity. Current opinion in allergy and clinical immunology. 2007. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007. Man Celeste B L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics. 2007. Ueda Kentaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical pharmacology and therapeutics. 2006. Oscarson Mikael, et al. PubMed
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006. Seo Takayuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and genomics. 2006. Hung Shuen-Iu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenetics and genomics. 2006. Alfirevic Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
A marker for Stevens-Johnson syndrome ...: ethnicity matters. The pharmacogenomics journal. 2006. Lonjou C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. The pharmacogenomics journal. 2006. Dlugos D J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proceedings of the National Academy of Sciences of the United States of America. 2005. Tate Sarah K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. European journal of clinical pharmacology. 2005. Nakajima Yukiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. European journal of clinical pharmacology. 2004. Ucar M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2002. Luo Gang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 2001. Pirmohamed M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & therapeutics. 2000. Hiemke C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions. Pharmacogenetics. 1998. Leeder J S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica; the fate of foreign compounds in biological systems. 1998. Tassaneeyakul W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The emerging role of cytochrome P450 3A in psychopharmacology. Journal of clinical psychopharmacology. 1995. Ketter T A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?. Therapeutic drug monitoring. 1995. Svinarov D A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?. Thérapie. 1992. Bonnet P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Elevated antidepressant plasma levels after addition of fluoxetine. The American journal of psychiatry. 1989. Aranow A B, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0228-2143-10
DrugBank:
DB00564
ChEBI:
3387
KEGG Compound:
C06868
KEGG Drug:
D00252
PubChem Compound:
2554
PubChem Substance:
46507583
7847318
Drugs Product Database (DPD):
2241882
ChemSpider:
2457
Therapeutic Targets Database:
DAP000129
FDA Drug Label at DailyMed:
a3360ae2-3ead-40bc-a967-2abecc9f9b7c

Clinical Trials

These are trials that mention carbamazepine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.